Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The ASH Annual Meeting is the world's premier event in malignant & non-malignant hematology. The meeting provides an invaluable educational experience and an opportunity to review thousands of scientific abstracts highlighting updates in the hottest topics in hematology. Network with top minds in the field, as well as a global community of more than 20,000 hematology professionals from every subspecialty.

ASH 2015

05–08 December 2015 | Orlando, FL

ASH 2015

05–08 December 2015 | Orlando, FL

The ASH Annual Meeting is the world's premier event in malignant & non-malignant hematology. The meeting provides an invaluable educational experience and an opportunity to review thousands of scientific abstracts highlighting updates in the hottest topics in hematology. Network with top minds in the field, as well as a global community of more than 20,000 hematology professionals from every subspecialty.

Overview of a Phase I clinical trial using zanubrutinib (formerly BGB-3111) for the treatment of relapsed CLL 3:21
Overview of a Phase I clinical trial using zanubrutinib (formerly BGB-3111) for the treatment of relapsed CLL
Constantine Tam • 4 Dec 2015
Importance of Bcl-2-targeted therapies 2:52
Importance of Bcl-2-targeted therapies
John Gribben et al. • 4 Dec 2015
Highlights of ASH in CLL 1:35
Highlights of ASH in CLL
John Gribben et al. • 4 Dec 2015
Overview of new combination therapies in acute myeloid leukemia (AML) 3:59
Overview of new combination therapies in acute myeloid leukemia (AML)
Naval Daver • 4 Dec 2015
Overview of the RESONATE-2 clinical trial of ibrutinib as front-line therapy 1:26
Overview of the RESONATE-2 clinical trial of ibrutinib as front-line therapy
Peter Hillmen • 4 Dec 2015
Overview of a promising new study of venetoclax in patients with CLL 3:40
Overview of a promising new study of venetoclax in patients with CLL
Jacqueline Barrientos • 6 Jan 2016
Overview of a Phase Ib study of venetoclax and obinutuzumab in CLL 3:15
Overview of a Phase Ib study of venetoclax and obinutuzumab in CLL
Martin Dyer • 4 Dec 2015
Follow-up results of looking at treatment with ibrutinib on CLL patient survival and adverse events 2:21
Follow-up results of looking at treatment with ibrutinib on CLL patient survival and adverse events
Jacqueline Barrientos • 4 Dec 2015
The future of CLL treatment 1:16
The future of CLL treatment
Michael Hallek • 4 Dec 2015
Challenges associated with long-term therapies in CLL 4:33
Challenges associated with long-term therapies in CLL
Michael Hallek • 4 Dec 2015
ASH 2015 highlights by Prof. Michael Hallek 1:50
ASH 2015 highlights by Prof. Michael Hallek
Michael Hallek • 4 Dec 2015
Overview of the clinical trial of ibrutinib vs chlorambucil as front-line therapy 1:14
Overview of the clinical trial of ibrutinib vs chlorambucil as front-line therapy
Véronique Leblond • 4 Dec 2015
The impact of the clinical trial of venetoclax (ABT-199) and obinutuzumab in CLL 0:58
The impact of the clinical trial of venetoclax (ABT-199) and obinutuzumab in CLL
Thomas Kipps • 4 Dec 2015
Ibrutinib vs chlorambucil in CLL patients not suitable for chemotherapy 5:10
Ibrutinib vs chlorambucil in CLL patients not suitable for chemotherapy
Thomas Kipps • 4 Dec 2015
The importance of targeting proliferating and quiescent cells in CLL 1:12
The importance of targeting proliferating and quiescent cells in CLL
Peter Hillmen • 4 Dec 2015
Can we afford to have CLL patients on a therapy for the rest of their lives? 1:37
Can we afford to have CLL patients on a therapy for the rest of their lives?
John Gribben et al. • 4 Dec 2015

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals